n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Arthritis, Rheumatoid

n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine has been researched along with Arthritis, Rheumatoid in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (75.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Borea, PA; Govoni, M; Padovan, M; Trotta, F; Varani, K; Vincenzi, F	1
Bar-Yehuda, S; Cohen, S; Fishman, P; Kerns, WD; Ochaion, A; Silverman, MH	1
Adawi, M; Caspi, D; Cohen, S; Cohn, I; Farbstein, M; Fishman, P; Fishman-Furman, S; Friedman, J; Green, L; Kerns, WD; Langevitz, P; Mader, R; Markovits, D; Molad, Y; Nahir, M; Ochaion, A; Reitblat, T; Rosner, I; Rozenbaum, M; Rubinow, A; Silverman, MH; Strand, V; Tanay, A; Tishler, M; Yehuda, SB	1
Bar-Yehuda, S; Barer, F; Cohen, S; Fishman, P; Madi, L; Ochayin, A	1

Reviews

2 review(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Arthritis, Rheumatoid

Article	Year
The role of adenosine receptors in rheumatoid arthritis. Autoimmunity reviews, 2010, Volume: 10, Issue:2 Topics: Adenosine; Animals; Arthritis, Rheumatoid; Humans; Inflammation; Purinergic Agonists; Receptors, Purinergic P1	2010
The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert opinion on investigational drugs, 2007, Volume: 16, Issue:10 Topics: Adenosine; Adenosine A3 Receptor Agonists; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Leukocytes, Mononuclear; Membrane Proteins	2007

Trials

1 trial(s) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Arthritis, Rheumatoid

Article	Year
Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. The Journal of rheumatology, 2008, Volume: 35, Issue:1 Topics: Adenosine; Adenosine A3 Receptor Agonists; Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Receptor, Adenosine A3; Severity of Illness Index; Treatment Outcome	2008

Article

Year

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial.

The Journal of rheumatology, 2008, Volume: 35, Issue:1

Topics: Adenosine; Adenosine A3 Receptor Agonists; Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Receptor, Adenosine A3; Severity of Illness Index; Treatment Outcome

2008

Other Studies

1 other study(ies) available for n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine and Arthritis, Rheumatoid

Article	Year
Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. The Journal of rheumatology, 2007, Volume: 34, Issue:1 Topics: Adenosine; Arthritis, Rheumatoid; Gene Expression Regulation; Humans; Interleukin-2; Leukocytes, Mononuclear; Middle Aged; Mitogens; NF-kappa B; Promoter Regions, Genetic; Receptor, Adenosine A3; Tumor Necrosis Factor-alpha	2007

Article

Year

Overexpression of A3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level.

The Journal of rheumatology, 2007, Volume: 34, Issue:1

Topics: Adenosine; Arthritis, Rheumatoid; Gene Expression Regulation; Humans; Interleukin-2; Leukocytes, Mononuclear; Middle Aged; Mitogens; NF-kappa B; Promoter Regions, Genetic; Receptor, Adenosine A3; Tumor Necrosis Factor-alpha

2007